Related Experiment Video
Updated: Sep 20, 2026
Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
Retinopathy of prematurity: molecular pathology and therapeutic strategies
Hadas Mechoulam1, Eric A Pierce
1Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Insights
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. Therapies targeting angiogenic factors and basement membrane changes show promise for treating ROP, similar to other retinal diseases.
Area of Science:
- Ophthalmology
- Neonatology
- Genetics
Background:
- Retinopathy of prematurity (ROP) is an ischemia-induced proliferative retinopathy affecting premature infants.
- ROP is a major cause of pediatric visual impairment and blindness.
- It shares pathological similarities with diabetic retinopathy, central vein occlusion, and age-related macular degeneration.
Purpose of the Study:
- To review the pathophysiology of ROP, including its genetic components and neovascularization processes.
- To explore potential medical therapies for ROP based on current understanding and animal model studies.
Main Methods:
- Literature review of ROP pathophysiology, genetics, and therapeutic strategies.
- Analysis of animal models of oxygen-induced retinopathy to assess treatment efficacy.
Main Results:
- ROP involves complex retinal neovascularization driven by angiogenic factors like vascular endothelial growth factor.
- Potential therapies include modulators of angiogenic factors, basement membrane components, endogenous inhibitors (e.g., pigment epithelium derived factor), and anti-inflammatory drugs.
- These therapies have demonstrated efficacy in animal models.
Conclusions:
- Therapies targeting angiogenic factors and basement membrane changes show promise for ROP treatment.
- Some ROP therapies are currently in clinical trials for other retinal diseases and may be applicable to ROP in the future.
Abstract:
Retinopathy of prematurity (ROP) is an ischemia-induced proliferative retinopathy, which affects premature infants with low birth weight. It is a leading cause of visual impairment and blindness in children, and shares pathophysiological characteristics with other common ocular diseases such as diabetic retinopathy, central vein occlusion, and age-related macular degeneration. Pathologically similar inherited diseases such as Norrie disease suggest a possible genetic component in the susceptibility to ROP. The process of retinal neovascularization in ROP and in animal models of oxygen-induced retinopathy is complex, and involves angiogenic factors, such as vascular endothelial growth factor, and basement membrane components. Potential medical therapies for ROP, including modulators of angiogenic factors, inhibitors of basement membrane changes, endogenous inhibitors such as pigment epithelium derived factor, and anti-inflammatory drugs, have shown efficacy against neovascularization in several animal models. Some of these therapies are in clinical trials now for diabetic retinopathy and age-related macular degeneration, and in the future may prove efficacious for the treatment of ROP.
